Fig. 1

Single chAbs binding and neutralizing capacities toward SARS-CoV-2 variants. A The binding of anti-RBD chAbs to S-His protein of SARS-CoV-2 variants was probed by ELISA. Data for each RBD-chAb are representative of three independent experiments. Each assay was performed in triplicate, and data points represent the mean. B Neutralization assay of SARS-CoV-2 variant pseudoviruses with RBD-chAbs. Data for each RBD-chAb are representative of three independent neutralization experiments. Each assay was performed in triplicate, and data points represent the mean. C Neutralizing RBD-chAbs inhibit SARS-CoV-2 variants, Alpha, Gamma and Delta; infection was assessed by PRNT. The PRNT₅₀ value was calculated with Prism software. Each assay was performed in triplicate and all data points are shown, along with the mean ± SD